Latest News & Features
Big Pharma
Gene-sequencing giant to be punished for defying EC authority by acquiring cancer treatment firm say FT sources | EC concerns over anti-competitive effects could scupper controversial deal. 10 October 2023
Big Pharma
Genexa files lawsuit against KinderFarms relating to agave-based over-the-counter pain relief medicines for children | Accuses KinderFarm of ‘willful, intentional, and deliberate’ actions. 5 October 2023
Biotechnology
Both attorneys have ‘exceptional experience’ in life sciences and previously practised at Dechert. 5 October 2023
Big Pharma
Amneal Pharmaceuticals fends off CMP’s US lawsuit alleging infringement of the blood pressure treatment / Dispute centres on whether suspension agents were used in “substantially the same way”. 3 October 2023
Africa
Non-profit hails move but urges other big pharma companies to follow suit | To avoid litigation, manufacturers must ensure generic versions are of good quality, medically acceptable, and are used only in the selected low-and middle-income countries. 3 October 2023
Big Pharma
Teva’s patents protecting migraine drug ruled invalid | Lilly’s motion for a new trial denied | ‘The court does not reach this decision nor overturn a jury verdict lightly’ says Judge Alison Burroughs. 28 September 2023
Big Pharma
ANDA litigation expert brings chemical, biotech, and pharmaceutical experience to the firm. 26 September 2023
Americas
Agreement reached over intranasal ketamine royalties and patents | Yale and a professor agree to pay $1.5m to the US government and give up royalty rights. 26 September 2023
Big Pharma
An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown. 26 September 2023
Biotechnology
The spatial biology firm will appeal the Unified Patent Court’s preliminary injunction | NanoString accuses 10x of ‘misusing non-final court rulings…to eliminate competition in the spatial transcriptomics market’. 21 September 2023